Insulet Corporation (NASDAQ:PODD) Stock Has Consensus Price Target of $195.40

by · The Markets Daily

Shares of Insulet Corporation (NASDAQ:PODD – Get Free Report) have received a consensus rating of “Hold” from the twenty-six ratings firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $195.40.

Several brokerages recently weighed in on PODD. Wells Fargo & Company cut shares of Insulet from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $255.00 to $144.00 in a research note on Wednesday, August 5th. Royal Bank Of Canada reduced their target price on Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Robert W. Baird set a $175.00 target price on shares of Insulet in a research report on Thursday, August 6th. Wall Street Zen lowered shares of Insulet from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 9th. Finally, Oppenheimer downgraded shares of Insulet from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th.

View Our Latest Analysis on PODD

Insulet Price Performance

Shares of NASDAQ:PODD opened at $131.69 on Wednesday. Insulet has a 52-week low of $126.40 and a 52-week high of $354.88. The company has a market capitalization of $9.13 billion, a PE ratio of 24.61, a price-to-earnings-growth ratio of 1.04 and a beta of 1.11. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The company has a fifty day moving average of $144.92 and a 200-day moving average of $162.47.

Insulet (NASDAQ:PODD – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. During the same quarter last year, the business posted $1.17 EPS. Insulet’s revenue for the quarter was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities analysts predict that Insulet will post 6.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Insulet

Several institutional investors have recently added to or reduced their stakes in PODD. BlackRock Inc. bought a new position in shares of Insulet during the 2nd quarter worth about $1,018,582,000. Norges Bank purchased a new position in shares of Insulet in the 4th quarter worth approximately $300,794,000. Arrowstreet Capital Limited Partnership grew its holdings in shares of Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after acquiring an additional 1,011,369 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Insulet by 1.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 768,066 shares of the medical instruments supplier’s stock valued at $218,315,000 after acquiring an additional 10,254 shares during the last quarter. Finally, Westfield Capital Management Co. LP lifted its holdings in Insulet by 91.9% during the fourth quarter. Westfield Capital Management Co. LP now owns 386,468 shares of the medical instruments supplier’s stock worth $109,850,000 after acquiring an additional 185,081 shares during the period.

Insulet Company Profile

(Get Free Report)

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet’s product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.

See Also